-
Jan 16, 2025 | 00010-9/abstract&sz=64)
annallergy.org | Alan D. Irvine
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes Children's Health Ireland (CHI) at Crumlin, Dublin D12 N512, Ireland Publication History: Received December 2, 2024; Revised January 8, 2025; Accepted January 8, 2025; Published online January 16, 2025 DOI: 10.1016/j.anai.2025.01.010Also available on...
-
Jun 20, 2024 | 
reference.medscape.com | Alan D. Irvine
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Atopic dermatitis (AD) is a chronic inflammatory skin condition, with incessant pruritus as its hallmark symptom. The disease typically has an intermittent course of flares and remissions, often occurring for unexplained reasons.
-
Apr 25, 2024 | 
reference.medscape.com | Alan D. Irvine
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. A 28-year-old White woman in the United States presents for evaluation due to a recent exacerbation of her psoriasis. She was originally diagnosed by her primary care provider a few months ago and prescribed clobetasol propionate, which controlled her symptoms for a few months.
-
Apr 12, 2024 | 
dermatologytimes.com | Alan D. Irvine
April 12, 2024Alan Irvine, MD, DSc, shares insights on the impact of ruxolitinib on quality of life in pediatric patients and 2024 AAD research presentations to take into consideration.
-
Apr 12, 2024 | 
dermatologytimes.com | Alan D. Irvine
In this Dermatology Times Expert Perspectives series, 5 experts delve into the multifaceted aspects of pediatric atopic dermatitis care including demographic variances to long-term safety and efficacy, comparative analyses, key takeaways from recent research, personalized approaches, and future research directions. Discover clinical insights into the role of ruxolitinib (Opzelura) in addressing critical challenges and enhancing patient outcomes.
-
Feb 15, 2024 | 
reference.medscape.com | Alan D. Irvine
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Psoriasis is a complex, inflammatory condition that causes scaly patches on the elbows, knees, scalp, and other parts of the body and can also affect the joints.
-
Jan 4, 2024 | 
reference.medscape.com | Alan D. Irvine
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Psoriasis is a common inflammatory disease of the skin. While the condition is primarily characterized by its dermatologic manifestations, it is a chronic, multisystem disorder. Approximately 30% of patients with psoriasis go on to develop immune-mediated psoriatic arthritis (PsA).
-
Dec 10, 2023 | 
dermatologytimes.com | Emma Andrus |Alan D. Irvine
Alan Irvine, MD, DSc, is a consultant dermatologist and a professor of dermatology at Trinity College Dublin, Ireland. At the 2023 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference on December 10, Irvine presented a session titled, "The Biological Clock is Ticking for Atopic Dermatitis." Irvine spoke with Dermatology Times to discuss highlights and takeaways from his session, the evolving treatment landscape of atopic dermatitis, and more. Q&AAlan Irvine, MD, DSc: I'm Alan Irvine.
-
Oct 4, 2023 | 
nature.com | Ashley Budu-Aggrey |Anna Kilanowski |Maria K Sobczyk |Suyash Shringarpure |Ruth E. Mitchell |Kadri Reis | +68 more
AbstractAtopic dermatitis (AD) is a common inflammatory skin condition and prior genome-wide association studies (GWAS) have identified 71 associated loci. In the current study we conducted the largest AD GWAS to date (discovery N = 1,086,394, replication N = 3,604,027), combining previously reported cohorts with additional available data.
-
Oct 2, 2023 | 
deutsch.medscape.com | Alan D. Irvine
close Sind Sie sicher, dass Sie sich ausloggen wollen? Die Psoriasis (Schuppenflechte) zeichnet sich durch eine Hyperproliferation der Keratinozyten in der Epidermis und eine erhöhte epidermale Zellerneuerungsrate aus. Weltweit sind etwa 125 Millionen Menschen von dieser Hauterkrankung betroffen. Sie betrifft die Haut und die Gelenke und führt zu Anomalien in anderen Systemen.
